Open AccessIneffectiveness of Intermittent Hemodialysis in a Critically Ill COVID-19 Patient: A Case of Persistent Heparin-Induced Hyperkalemia
Author(s) -
Yannick Mayamba Nlandu,
Yannick Mompango Engole,
Marie-France Mboliassa,
Théodore-Junior M. Sakaji,
Patrick Kobo,
Patrick Boloko,
Pally Mafuta,
Joseph P. Tsangu,
Karel Van Echkout,
Jean-Pierre M. Kanku,
G Kalifa,
Rodolphe Ahmed,
Justine Busanga Bukabau
Publication year - 2022
Publication title -
case reports in nephrology
Language(s) - English
Resource type - Journals
eISSN - 2090-6641
pISSN - 2090-665X
DOI - 10.1155/2022/8613656
Subject(s) - hyperkalemia , medicine , heparin , context (archaeology) , hemodialysis , intensive care unit , intensive care medicine , hypoaldosteronism , aldosterone , adrenal insufficiency , critically ill , renin–angiotensin system , blood pressure , paleontology , biology
Heparin is widely used in the intensive care unit despite the risk of bleeding it can cause. Although it is rarely reported, hyperkalemia is one of the side effects associated with heparin therapy (unfractionated or fractionated heparin). It would be secondary to hypoaldosteronism by blocking the biosynthesis of aldosterone in the adrenal gland and often appears in context of prolonged heparin therapy or inappropriate renin production in elderly, diabetic, and kidney insufficiency patients. We report a case of persistent hyperkalemia in a diabetic COVID-19 patient treated with curative heparin in the context of severe COVID-19.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom